Evonile Pharma (formerly Novartis India) is moving ahead with its Rs 900 crore rights issue. The company has scheduled board and committee meetings for November 4, 2026, to finalize the issue price, entitlement ratio, and record date. Having secured in-principle BSE approval, this meeting will define the key terms for eligible shareholders participating in the partly paid-up equity share offering.
Evonile Pharma Advances Rs 900 Crore Rights Issue Plans
Aggregate fundraising amount is Rs 900 crore; Board meets November 4 to finalize terms.
Reader Takeaway: The upcoming meeting will lock in pricing and record dates, directly impacting shareholder subscription eligibility.
What just happened
Evonile Pharma Limited has announced a critical board and committee meeting scheduled for November 4, 2026. This follows the company receiving in-principle approval from the BSE on October 30, 2026, for its proposed rights issue. The company aims to raise up to Rs 900 crore through the issuance of partly paid-up equity shares.
Why this matters
The November 4 meeting is a pivotal step in the capital-raising process. The Board of Directors will review and approve the 'Letter of Offer,' while the Rights Issue Committee will finalize the granular details of the transaction. For existing investors, the decisions made on this day—specifically the issue price, entitlement ratio, and the record date—are essential to determining the cost of participation and eligibility for the offering.
What to track next
Shareholders should closely monitor the subsequent regulatory filings from the BSE on or after November 4. These filings will contain the final issue price, the specific ratio at which shares will be offered, and the record date that determines which shareholders are entitled to participate. These metrics are fundamental for investors looking to assess the dilution impact and the valuation of the upcoming rights issue.